Systemic lupus erythematosus and pregnancy.
Systemic lupus erythematosus (SLE) may improve, exacerbate or be unchanged during pregnancy. The activity of SLE at the time of conception has a major influence on pregnancy outcome: SLE patients with quiescent disease do well, while those with active, uncontrollable disease have a high abortion rate. There are specific autoantibodies that confer a high risk of abortion (e.g., IgG antiphospholipid antibodies). There are others, such as anti-Ro/SSA and anti-La/SSB, which confer a risk for neonatal lupus that includes lupus dermatitis, congenital complete heart block, thrombocytopenia and cholestatic jaundice, in order of their relative frequencies.
Reichlin
M
M
Oklahoma Medical Research Foundation, Department of Medicine, University of Oklahoma College of Medicine, Oklahoma City 73104, USA. morris-reichlin@omrf.ouhsc.edu
D000022:Abortion, Spontaneous / Q000209:etiology*; D017152:Antibodies, Antiphospholipid / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000209:etiology / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D011256:Pregnancy Outcome; D011379:Prognosis; D012307:Risk Factors
D017152:Antibodies, Antiphospholipid; D001323:Autoantibodies